Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APT-002S
- Development stage
- Unknown
- Lead developer
- Aptah Bio
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
APT-002S is an investigational RNA therapy being developed by Aptah Bio for the treatment of melanoma. It is based on the company's proprietary RNA WiCo™ (RNA Wide-Control) platform, which is designed to target the U1 small nuclear ribonucleoprotein (U1 snRNP). By modulating the activity of U1 snRNP, APT-002S aims to regulate RNA splicing and processing pathways that are frequently dysregulated in oncogenic states. This mechanism is intended to correct or inhibit the production of proteins that drive tumor progression and survival in melanoma cells. The asset is currently in the proof-of-concept stage of development.
Beyond the preview
Go deeper on APT-002S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APT-002S.